Cargando…
Tumorigenic role of Musashi-2 in aggressive mantle cell lymphoma
SOX11 overexpression has been associated with aggressive behavior of mantle cell lymphomas (MCL). SOX11 is overexpressed in embryonic and cancer stem cells (CSC) of some tumors. Although CSC have been isolated from primary MCL, their relationship to SOX11 expression and contribution to MCL pathogene...
Autores principales: | Sureda-Gómez, Marta, Balsas, Patricia, Rodríguez, Marta-Leonor, Nadeu, Ferran, De Bolòs, Anna, Eguileor, Álvaro, Kulis, Marta, Castellano, Giancarlo, López, Cristina, Giné, Eva, Demajo, Santiago, Jares, Pedro, Martín-Subero, José I., Beà, Silvia, Campo, Elias, Amador, Virginia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898029/ https://www.ncbi.nlm.nih.gov/pubmed/36509891 http://dx.doi.org/10.1038/s41375-022-01776-x |
Ejemplares similares
-
P1295: DECIPHERING THE ROLE OF MSI2 AS A REGULATOR OF MANTLE CELL LYMPHOMA STEM-LIKE PROPERTIES
por: Sureda-Gómez, M., et al.
Publicado: (2022) -
MALAT1 expression is associated with aggressive behavior in indolent B-cell neoplasms
por: Fernández-Garnacho, Elena María, et al.
Publicado: (2023) -
Identification of Methylated Genes Associated with Aggressive Clinicopathological Features in Mantle Cell Lymphoma
por: Enjuanes, Anna, et al.
Publicado: (2011) -
Robust CRISPR-Cas9 Genetic Editing of Primary Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Cells
por: Mateos-Jaimez, Judith, et al.
Publicado: (2023) -
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial
por: Giné, Eva, et al.
Publicado: (2022)